- Home
- TCBS vs ANL Comparison
TCBS vs ANL Comparison
Compare TCBS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | TCBS | ANL |
|---|---|---|
| Founded | 1934 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.3M | 52.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | TCBS | ANL |
|---|---|---|
| Price | $16.00 | $1.40 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.0K | ★ 11.2K |
| Earning Date | 11-07-2025 | 11-07-2025 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $15,268,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.44 | ★ N/A |
| Revenue Growth | ★ 54.88 | N/A |
| 52 Week Low | $14.85 | $1.10 |
| 52 Week High | $19.40 | $2.99 |
Technical Indicators
Market Signals| Indicator | TCBS | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 40.01 |
| Support Level | $15.90 | $1.32 |
| Resistance Level | $15.95 | $1.55 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 96.15 | 23.19 |
Price Performance
Historical ComparisonAbout TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.